News | March 15, 2023
LifeSigns raises Pre-Series A
A funding to expand operations and provide better patient care
A funding to expand operations and provide better patient care
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Collaboration supports multiple discovery efforts, including vaccines
Subscribe To Our Newsletter & Stay Updated
